Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats

Alice Blet(Inserm), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Evelyne Polidano(Inserm), Peter Pickkers(Radboud University Nijmegen), Jane‐Lise Samuel(Université Paris Cité), Paul-Robert Kounde(Inserm), Malha Sadoune(Inserm), Benjamin Deniau(Inserm), Christopher Geven(Radboud University Nijmegen), Anaïs Caillard
Intensive Care Medicine Experimental
May 15, 2019
10.1186/s40635-019-0255-0
Cited by 32

Related Papers

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
|European Heart Journal|2008|2.7k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Journal of Heart Failure|2022|2.1k